BioRegenx, Inc. (BRGX) Fair Value 2026

BRGX · Health Information Services ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

5.1 /10

32 fundamental signals · 2 models active

Value Trap Risk

LOW (33/100)

Quick Summary — As of 2026-08-27, BioRegenx, Inc. (BRGX) trades at $0.01, versus a $0.00 median fair value across its 2 active models — 47.4% below the current price. QOC: 5.1/10. Value Trap Risk: 33/100 (LOW). 2/13 models active. Within that set, the Bayesian DCF component alone returns $0.00.

Key Facts

Ticker
BRGX
Price
$0.01
Quality Score
5.1/10
Value Trap Risk
33/100
Models Active
2/13
Last Updated
Strength: 2 independent models provide multi-angle coverage
Risk: Majority of models suggest overvaluation

Is BioRegenx, Inc. (BRGX) Undervalued or Overvalued in 2026?

According to CirclFi’s 2-model valuation engine, BioRegenx, Inc. (BRGX) appears overvalued as of : the median of 2 independent fair value estimates is $0.00, 47.4% below the current price of $0.01. Estimates range from $0.00 to $0.00. BRGX scores 5.1/10 on fundamental quality and 33/100 on value-trap risk.

For context, the median US equity CirclFi rates trades at an implied -23.7% versus its own 13-model consensus, across 3,801 rated companies as of 2026-08-27. BRGX’s -47.4% gap is wider than that market norm, and the Health Information Services sector median is +4.5%. Full market index →

This verdict compares price to intrinsic value only — it is not a buy or sell rating. For the decision case (bull vs bear arguments, risk factors, peers), read Should You Buy BioRegenx, Inc. Stock in 2026? →

What Fair Value Does Each Model Give BRGX?

2 Intrinsic Value Models vs. Current Price ($0.01)

Core Models (Unlocked)
Model Fair Value Upside
Intrinsic · High Conviction
 $0.00 -43.6%
Intrinsic · High Conviction
 $0.00 -51.2%

All Models Active

All 2 models are displayed above.

What Is BioRegenx, Inc. (BRGX) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, BioRegenx, Inc.'s intrinsic value is estimated at $0.00, suggesting the stock is overvalued at its current price of $0.01. With 2 out of 2 models flagging downside (-47.4% vs price), the market may be pricing in unsustainable growth.

What Do the Models Say About BRGX?

2 of 13 models are currently active for BRGX. All 2 active models suggest the stock trades above fair value. Taken together, their median fair value for BRGX is $0.00 — the figure CirclFi publishes as this stock's fair value. One component of that median, the Bayesian DCF, returns $0.00 on its own, implying -43.6% downside from the current price. See which stocks rank higher →

How Does BRGX Rank in Health Information Services?

Among 55 Health Information Services stocks, BRGX ranks #41 by Quality of Company score. CirclFi's QOC score of 5.1/10 evaluates 32 fundamental signals. A score of 5.1 reflects mixed fundamentals.

See all Most Undervalued Health Information Services Stocks →

BioRegenx, Inc. operates in a competitive landscape where fundamental quality metrics are key differentiators for long-term value creation.

Is BRGX a Value Trap?

CirclFi's Value Trap algorithm assigns BRGX a score of 33/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

2 of 13 models are active for BioRegenx, Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Quality of Company (QOC) framework, which evaluates 32 signals including margin stability, revenue growth trajectory, leverage, and free cash flow generation, BioRegenx, Inc. is rated at 5.1/10. This moderate-tier score shows mixed signals across our quality framework with notable weaknesses.

Models cluster within a tight range (+7.6% spread), increasing conviction. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every BRGX valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across BRGX's 2 active models, average confidence is 59%. Moderate confidence indicates reasonable fit.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy BioRegenx, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Health Information Services Stocks Should You Also Analyze?

11 related Health Information Services stocks with 13-model coverage

ACONAclarion, Inc.QOC 5.1LGMKLogicMark, Inc.QOC 4.9CTEVClaritev CorporationQOC 5.6MGRXMangoceuticals, Inc.QOC 4.8AMWLAmerican Well CorporationQOC 5.8WORXSCWorx CorpQOC 4.8MNDRMobile-health Network SolutionsQOC 2.6TXG10x Genomics, Inc.QOC 7.6HNGEHinge Health, Inc.QOC 6.4DOCSDoximity, Inc.QOC 9.6HQYHealthEquity, Inc.QOC 9.5

Read investment analysis: ACON · LGMK · CTEV · MGRX · AMWL · WORX · MNDR · TXG · HNGE · DOCS · HQY

Which Other Stocks Have a Similar Quality Score to BRGX?

7 companies across all industries closest to BRGX’s Quality of Company score of 5.1/10.

TRWDTradewinds UniversalQOC 5.1KRROKorro Bio, Inc.QOC 5.1DYNDyne Therapeutics, Inc.QOC 5.1SLNDSouthland Holdings, Inc.QOC 5.1MACIMelar Acquisition Corp. IQOC 5.1BNBXBNB Plus Corp.QOC 5.1NVDANVIDIA CorporationQOC 10.0

Read investment analysis: TRWD · KRRO · DYN · SLND · MACI · BNBX · NVDA

Where Does BRGX Sit in CirclFi's Health Information Services Rankings?

BRGX is ranked against every other Health Information Services stock CirclFi covers in each of these screens.

See all Health Information Services stocks ranked →

What Else Do Investors Ask About BioRegenx, Inc.’s Valuation?

What is BioRegenx, Inc.'s intrinsic value in 2026?

CirclFi puts BioRegenx, Inc. (BRGX)'s intrinsic value at $0.00 — the median of 2 independent model estimates as of 2026-08-27, ranging from $0.00 to $0.00. One component of that median, the Bayesian DCF, runs 10,000 Monte Carlo simulations with jump-diffusion and returns $0.00 on its own. The Quality of Company score is 5.1/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is BRGX overvalued or undervalued right now?

At $0.01, 0 of 2 active models suggest BRGX may be undervalued, while 2 indicate potential overvaluation. The median of all 2 fair value estimates is $0.00, 47.4% below the current price of $0.01 — a consensus view that BRGX is overvalued. The assessment depends on which methodology best fits BioRegenx, Inc.'s business model in Health Information Services.

What does a Quality of Company score of 5.1 mean for BRGX?

BioRegenx, Inc.'s QOC of 5.1/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on BRGX?

CirclFi analyzes BRGX with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 2 of 13 are active for this stock. Read the full methodology →

Is BRGX a value trap in 2026?

BioRegenx, Inc.'s Value Trap score is 33/100 (LOW). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

Cite this analysis — “According to CirclFi’s 2-model valuation engine, BioRegenx, Inc. (BRGX) has a median fair value of $0.00 — 47.4% below the current price of $0.01 — as of 2026-08-27.” Source: circlfi.com/stock/BRGX/ · Methodology
Primary sources for this BRGX valuation
  • Financial statements: BioRegenx, Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0001593184) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for BRGX as of ; valuations recomputed .